Search
E1v1.11
go.drugbank.com/drugs/DB18363ExperimentalE1v1.11 is an antisense oligonucleotide targeting the _SMN2_ gene which is under investigation for the treatment of spinal muscular atrophy (SMA).[L48196]
Denifanstat
go.drugbank.com/drugs/DB17576InvestigationalDue to its antineoplastic activities, it is being investigated for various cancers.
D-JNKI-1
go.drugbank.com/drugs/DB05660InvestigationalA synthetic, cell permeable peptide that blocks the MAPK-JNK signal pathway; has potential therapeutic value for long-term protection of both the morphological integrity and physiological function of the
Allovectin-7
go.drugbank.com/drugs/DB17439InvestigationalAllovectin-7 or allovectin-7(r) is a lipid complex that contains the DNA sequences encoding HLA-B7 and beta-2 microglobulin. … It was discontinued after it failed to improve the objective response rate or overall survival versus first-line chemotherapy in malignant melanoma.[A255207]
Acetoxolone
go.drugbank.com/drugs/DB13640ExperimentalCategories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)Bilberry
go.drugbank.com/drugs/DB14235ApprovedWithdrawnSynonyms: Dried billberry fruit (vaccinium myrtillus l.), Fresh billberry fruit (vaccinium myrtillus l.)Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesMidomafetamine
go.drugbank.com/drugs/DB01454IllicitInvestigationalIt is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. … It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesBiomed 101
go.drugbank.com/drugs/DB05851InvestigationalBiomed 101 is investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma. Biomed 101 is a solid.
TAK-243
go.drugbank.com/drugs/DB15013InvestigationalTAK-243 is under investigation in clinical trial NCT03816319 (TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic
NN344
go.drugbank.com/drugs/DB05115ExperimentalThe product is intended for basal insulin treatment of diabetes mellitus. … NN344 is a neutral, soluble long-acting human insulin analogue with 24 hour coverage by once daily injection. NN344 has a very flat and predictable action profile.